Inve India ▾

Dr. Reddy's Laboratories share price & results

Dr. Reddy's Laboratories Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Global pharma company making generics, biosimilars, APIs and OTC/consumer health products across 88 countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue5,573 ₹ crore+20.7% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin20.0 %+10.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit696 ₹ crore+79.8% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity7.22 %−6.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin5.95 %+1.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-3.53 %−13.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

2 of 6 judged targets kept · 8 open · verdicts reflect calls analysed to Q1 FY27.

Dr. Reddy's Laboratories Limited management guidance track record on Inve: 14 targets tracked across analysed earnings calls (2 achieved, 4 missed, 8 open).

TargetOriginal wordingSaidLatest callVerdict
Semaglutide Launch (Canada)Beginning of January 2026
Call transcript, Q1 FY26 · 23 Jul 2025		Q1 FY26Q1 FY27:Promise was previously achieved. No new information.
Call transcript, Q1 FY27 · 9 Jul 2026		Achieved
SG&A Spend as % of Sales28 to 29%, not a 30%
Call transcript, Q1 FY26 · 23 Jul 2025		Q1 FY26Q1 FY27:Promise period has passed. No new information.
Call transcript, Q1 FY27 · 9 Jul 2026		Ghosted
Semaglutide Pen Capacity12 million pens in FY27
Call transcript, Q1 FY26 · 23 Jul 2025		Q1 FY26Q1 FY27:Due to an API impurity issue halting supply, the FY27 target is now revised down to 6-7 million pens, to be supplied in H2 FY27. This is a significant downward revision from the original 12 million pen target for FY27.
Call transcript, Q1 FY27 · 9 Jul 2026		Revised Down

Source: Inve Guidance Tracker for Dr. Reddy's Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Dr. Reddy's Laboratories Limited's 14 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,310 −0.07% · −₹0.9

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +2.1% 1Y

₹1.1k₹1.2k₹1.3k₹1.3k₹1.4kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 24 Oct 2025Q2 FY26 — 28 Oct 2025Q4 FY26 — 12 May 2026Q1 FY27 — 9 Jul 2026

1Y: ₹1,283.6 on 24 Oct 2025 → ₹1,310. High ₹1,375.7 (29 Jun 2026), low ₹1,135.6 (28 Jul 2026).

Previous close
₹1,310.9
Market cap
₹1.1L Cr
52-week range
₹1,135.6 – ₹1,375.7
One year
+2.00%
Price to earnings (TTM to Sept 2026)
39.27×
Return on equity (TTM to Sept 2026)
7.22%

Overview

Symbol
NSE:DRREDDY
Exchange
NSE
Currency
INR

What Dr. Reddy's Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations (including biosimilars), OTC/consumer-health products, innovative products and custom pharmaceutical services. It sells across three broad segments - Global Generics (branded and unbranded generic finished dosages), PSAI (Pharmaceutical Services and Active Ingredients, including a CDMO business under subsidiary Aurigene Pharmaceutical Services) and Others - with focus therapeutic areas spanning Oncology, Central Nervous System, Pain Management, Gastro-Intestinal and Cardiovascular. Its largest markets are the USA, India, Russia & CIS, China, Brazil and Europe, supplemented by an oncology-focused R&D subsidiary, Aurigene Oncology, and a consumer-health (NRT) portfolio integrated across more than 30 countries.

Segments

  • Global Generics
  • PSAI (Pharmaceutical Services and Active Ingredients)
  • Others
Countries served
88
Manufacturing facilities globally
24
Employees globally
27,527
R&D facilities
5 state-of-the-art centres
R&D scientists
2,769
Nationalities in workforce
64
Founded 1984Headquarters Hyderabad, Telangana, IndiaEmployees 27,527 (March 31, 2026) Company website

How the price took the results

close before → close after

Q1 FY27
−5.9%
9 Jul
Q4 FY26
−1.8%
12 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Dr. Reddy's Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Dr. Reddy's Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Dr. Reddy's Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.